Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Retained Earnings (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Retained Earnings data on record, last reported at $381000.0 in Q4 2025.

  • For Q4 2025, Retained Earnings rose 112.85% year-over-year to $381000.0; the TTM value through Dec 2025 reached $381000.0, up 112.85%, while the annual FY2025 figure was $381000.0, 112.85% up from the prior year.
  • Retained Earnings reached $381000.0 in Q4 2025 per TARS's latest filing, up from -$418.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $381000.0 in Q4 2025 and bottomed at -$418.3 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$140.2 million, with a median of -$72.7 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 9050.0% in 2024, then plummeted 611534.92% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$31.8 million in 2021, then soared by 99.77% to -$74000.0 in 2022, then skyrocketed by 97.3% to -$2000.0 in 2023, then surged by 9050.0% to $179000.0 in 2024, then surged by 112.85% to $381000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $381000.0 in Q4 2025, -$418.3 million in Q3 2025, and -$405.7 million in Q2 2025.